{"id":1623,"date":"2026-05-30T06:53:54","date_gmt":"2026-05-30T06:53:54","guid":{"rendered":"https:\/\/one-peptides.com\/selank-research-on-anxiolytic-effects\/"},"modified":"2026-10-03T11:32:44","modified_gmt":"2026-10-03T11:32:44","slug":"selank-research-on-anxiolytic-effects","status":"publish","type":"post","link":"https:\/\/one-peptides.com\/es\/selank-research-on-anxiolytic-effects\/","title":{"rendered":"Selank – research on anti-anxiety effects"},"content":{"rendered":"
\n\tHome<\/a>\n<\/span>\u00bb<\/span>\n\tRegeneration & research peptides<\/a>\n<\/span>\u00bb<\/span>\n\tSelank \u2013 research on anti-anxiety effects\n<\/span><\/div><\/div>\n

In 1970, the American immunologist Victor Najjar described a short, natural tetrapeptide, which he named tuftsin<\/strong> (from Tufts University, where he worked). The Thr-Lys-Pro-Arg sequence comes from the Fc fragment of the immunoglobulin G heavy chain (positions 289\u2013292) and is formed physiologically by the enzymatic cleavage of IgG in the spleen and by neutrophil membrane enzymes. Function: stimulating the phagocytic activity of macrophages and neutrophils. Tuftsin was initially treated solely as an immunomodulatory peptide.<\/p>\n

Two decades later, a group of Russian researchers at the Institute of Molecular Genetics in Moscow – led by Nina Myasoedov and with the participation of Ashmarin’s team – began to test synthetic analogues of tuftsin for neurobiological activity. The hypothesis was not obvious: since tuftsin modulates immune functions, and the immune system is closely related to the stress axis (HPA) and emotional reactions, perhaps tuftsin analogues may have anxiolytic activity. The hypothesis turned out to be correct. In 1995, the team described Selank<\/strong> \u2014 heptapeptide with the sequence Thr-Lys-Pro-Arg-Pro-Gly-Pro, which showed strong anxiolytic effects in behavioral tests in animal models without sedation<\/strong> characteristic of benzodiazepines.<\/p>\n

This distinction\u2014anxiolysis without sedation\u2014is the central argument for Selank research. Classic benzodiazepines solve the problem of anxiety, but at the same time they introduce sedation, working memory disorders, ataxia and – with long-term administration – tolerance and addiction. Selank in animal models and clinical trials vs. medazepam does not show these side effects, offering a pharmacologically purer anxiolytic action profile.<\/p>\n

\n

\ud83d\udcd6 The following article is educational and is a review of published scientific literature about Selank. Most of the studies cited were conducted in animal models and in vitro; some clinical work comes from Russian-language literature, the validation of which in independent Western groups remains limited. The text does not constitute medical advice. The peptide from the One Peptides catalog is intended only for laboratory tests (Research Use Only).<\/p>\n<\/blockquote>\n

What is Selank – sequence, structure, origin<\/h2>\n

Selank is a synthetic heptapeptide sequence Thr-Lys-Pro-Arg-Pro-Gly-Pro<\/strong> (single letter: TKPRPGP). The first four amino acids correspond to the sequence of tuftsin<\/strong> \u2014 natural immunomodulatory peptide derived from the Fc fragment of IgG. C-terminal tripeptide Pro-Gly-Pro<\/strong> is a synthetic extension introduced intentionally to increase proteolytic stability, identical in design strategy to the other peptide of the Russian school – Semax.<\/p>\n

Chemical features important from a laboratory perspective:<\/p>\n